2020 Alzheimer's disease facts and figures
- PMID: 32157811
- DOI: 10.1002/alz.12068
2020 Alzheimer's disease facts and figures
Abstract
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the future challenges of meeting care demands for the growing number of people living with Alzheimer's dementia in the United States with a particular emphasis on primary care. By mid-century, the number of Americans age 65 and older with Alzheimer's dementia may grow to 13.8 million. This represents a steep increase from the estimated 5.8 million Americans age 65 and older who have Alzheimer's dementia today. Official death certificates recorded 122,019 deaths from AD in 2018, the latest year for which data are available, making Alzheimer's the sixth leading cause of death in the United States and the fifth leading cause of death among Americans age 65 and older. Between 2000 and 2018, deaths resulting from stroke, HIV and heart disease decreased, whereas reported deaths from Alzheimer's increased 146.2%. In 2019, more than 16 million family members and other unpaid caregivers provided an estimated 18.6 billion hours of care to people with Alzheimer's or other dementias. This care is valued at nearly $244 billion, but its costs extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are more than three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 23 times as great. Total payments in 2020 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $305 billion. As the population of Americans living with Alzheimer's dementia increases, the burden of caring for that population also increases. These challenges are exacerbated by a shortage of dementia care specialists, which places an increasing burden on primary care physicians (PCPs) to provide care for people living with dementia. Many PCPs feel underprepared and inadequately trained to handle dementia care responsibilities effectively. This report includes recommendations for maximizing quality care in the face of the shortage of specialists and training challenges in primary care.
Keywords: Alzheimer's dementia; Alzheimer's disease; Alzheimer's disease continuum; Biomarkers; Caregivers; Dementia; Dementia care training; Family caregiver; Geriatrician; Health care costs; Health care expenditures; Health care professional; Incidence; Long-term care costs; Medicaid spending; Medicare spending; Morbidity; Mortality; Prevalence; Primary care physician; Risk factors; Spouse caregiver.
© 2020 the Alzheimer's Association.
Similar articles
-
2021 Alzheimer's disease facts and figures.Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23. Alzheimers Dement. 2021. PMID: 33756057
-
2022 Alzheimer's disease facts and figures.Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14. Alzheimers Dement. 2022. PMID: 35289055
-
2023 Alzheimer's disease facts and figures.Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14. Alzheimers Dement. 2023. PMID: 36918389
-
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. PMID: 28876770 Free Books & Documents. Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Cited by
-
Therapy for Alzheimer's disease: Missing targets and functional markers?Ageing Res Rev. 2021 Jul;68:101318. doi: 10.1016/j.arr.2021.101318. Epub 2021 Mar 9. Ageing Res Rev. 2021. PMID: 33711510 Free PMC article. Review.
-
Cognitive tasks propagate the neural entrainment in response to a visual 40 Hz stimulation in humans.Front Aging Neurosci. 2022 Oct 6;14:1010765. doi: 10.3389/fnagi.2022.1010765. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36275007 Free PMC article.
-
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer's disease.Alzheimers Res Ther. 2020 Sep 14;12(1):109. doi: 10.1186/s13195-020-00670-x. Alzheimers Res Ther. 2020. PMID: 32928293 Free PMC article. Review.
-
Fenamates as Potential Therapeutics for Neurodegenerative Disorders.Cells. 2021 Mar 22;10(3):702. doi: 10.3390/cells10030702. Cells. 2021. PMID: 33809987 Free PMC article. Review.
-
Interactions between the apolipoprotein E4 gene and modifiable risk factors for cognitive impairment: a nationally representative panel study.BMC Geriatr. 2022 Dec 6;22(1):938. doi: 10.1186/s12877-022-03652-w. BMC Geriatr. 2022. PMID: 36474172 Free PMC article.
References
REFERENCES
-
- Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12(4):357-67.
-
- Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardos C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11(2):1048-56.
-
- Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65.
-
- Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804.
-
- Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: A longitudinal study. Lancet Neurol 2018;17(3):241-50.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials